Takeda Pharmaceutical (TAK) Receivables Refunds (2018 - 2025)
Historic Receivables Refunds for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $139.4 million.
- Takeda Pharmaceutical's Receivables Refunds fell 1037.41% to $139.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $139.4 million, marking a year-over-year decrease of 1037.41%. This contributed to the annual value of $103.7 million for FY2025, which is 4881.99% down from last year.
- Latest data reveals that Takeda Pharmaceutical reported Receivables Refunds of $139.4 million as of Q4 2025, which was down 1037.41% from $90.1 million recorded in Q3 2025.
- Over the past 5 years, Takeda Pharmaceutical's Receivables Refunds peaked at $513.6 million during Q4 2022, and registered a low of $90.1 million during Q3 2025.
- For the 5-year period, Takeda Pharmaceutical's Receivables Refunds averaged around $226.8 million, with its median value being $232.2 million (2023).
- As far as peak fluctuations go, Takeda Pharmaceutical's Receivables Refunds surged by 16624.67% in 2021, and later tumbled by 6463.13% in 2023.
- Takeda Pharmaceutical's Receivables Refunds (Quarter) stood at $357.2 million in 2021, then soared by 43.78% to $513.6 million in 2022, then tumbled by 64.63% to $181.6 million in 2023, then decreased by 14.37% to $155.5 million in 2024, then decreased by 10.37% to $139.4 million in 2025.
- Its Receivables Refunds stands at $139.4 million for Q4 2025, versus $90.1 million for Q3 2025 and $96.1 million for Q2 2025.